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Abstract 
Background: The main oncogenic action of CD99 and cyclin D1 biomarkers is 
referred to any mutation, amplification, and overexpression in cyclin D1 coding gene, 
altering cell cycle progression as the main mechanism observed in a variety of tumors. 
A few studies attempted to detect the overexpression of cyclin D1 and CD99 and in 
certain types of tumors such as Ewing's sarcoma and rhabdomyosarcoma. The present 
study aimed to assess the prevalence of CD99 and cyclin D1 overexpression in these 
two types of tumors. We also described this overexpression according to the patients 
and tumor indicators.  
Methods: This cross-sectional survey was performed on 30 consecutive patients 
with Ewing's sarcoma and 22 patients with rhabdomyosarcoma and hospitalized in 
Shafa hospital in Tehran between 2009 and 2014. The assessment of CD99 and cyclin 
D1 markers was based on immunohistochemical assessment using the formalin fixed 
and paraffin embedded tissue samples of the two tumors. 
Results: Almost all Ewing's sarcomas had membranous patterns of CD99 while 
this marker was negative in most patients with rhabdomyosarcoma. Therefore, detecting 
membranous CD99 could specifically detect Ewing's sarcoma and distinguish it from 
rhabdomyosarcoma. Moreover, contrary to rhabdomyosarcoma which is accompanied 
with lower cyclin D1 intensity, all Ewing's sarcomas were characterized by moderate 
to severe cyclin D1 intensity. Similarly, almost all those with Ewing's sarcoma had 
diffuse cyclin D1 extension; whereas, the pattern of cyclin D1 extension in rhab-
domyosarcoma was mostly negative or focal. 
Conclusion: The detection of CD99 and cyclin D1 overexpression and their 
intensity and extension patterns can specifically distinguish Ewing's sarcoma from 
rhabdomyosarcoma. 
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Ewing’s sarcoma (EWS) and 
rhabdomyosarcoma (RMS) are both 
categorized as small-round-blue-cell 
tumors (SRBCT), a group of 
malignant neoplasms sharing similar 
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histology with vastly different prognosis and 
treatment. Although the differential diagnosis of 
these lesions is of clinical importance, their dif-
ferentiation might be challenging, particularly if 
EWS arises in the soft-tissue component of the 
limb, known as extra-osseous EWS. Differentia-
tion of EWS from the solid-variant of alveolar 
RMS is also a histological challenge. Moreover, 
EWS may show atypical histologic morphologies, 
including spindle cell, large cell or 
“adamantinoma-like” features, as well as diffuse 
and abundant hyalinized matrix, which poses 
serious diagnostic problems with other 
malignancies.1-4  
Although CD99 and FLI-1 are currently the 
most accepted immunohistochemical (IHC) 
markers for EWS, their accuracy is controversial.4 
While CD99 is expressed in nearly all cases of 
EWS, it is also occasionally expressed in RMS.5 
Similarly, while antibodies against FLI-1 have 
been tested in EWS with a nearly high sensitivity, 
its specificity is still a matter of  debate.4,6,7 Actin, 
Myosin, Myoglobin, and Desmin have proven 
useful in the diagnosis of RMS; however, these 
markers lack absolute sensitivity and/or 
specificity.8,9 Thus, there is an increasing 
reluctance among oncologists to accept the 
diagnosis of EWS and RMS without cytogenetic 
and molecular genetic analysis of the known 
translocations.2, 9, 10 Nonetheless, the diagnosis 
of EWS and RMS continues to be based on 
morphology and IHC analyses because 
cytogenetic testing and/or molecular evaluation 
are not routinely available in a great majority of 
surgical pathology departments.4 Accordingly, 
several investigations have attempted to identify 
valuable IHC markers that might be conducive 
to the differentiation of EWS from its 
morphological mimics such as RMS. 
Cyclin D1 is an important regulator of cell 
cycle progression, and its overexpression has 
been associated with the development and 
progression of many types of cancer.1 In vitro 
studies have shown that cyclin D1 is 
overexpressed in EWS but not in RMS cell lines.12 
Subsequently, Magro et al. performed a 
comparative IHC analysis on the expression and 
distribution of cyclin D1 in a large series of soft 
tissue EWS and RMS in order to assess its 
potential usefulness in their differential diagnosis. 
Based on their results, overexpression of cyclin 
D1 in EWS/PNET could be exploitable as a 
diagnostic immunomarker for this tumor and its 
differentiation from RMS as well.3 However, 
there is not sufficient evidence on the diagnostic 
potential of cyclin D1 in EWS. 
Accordingly, the objective of the current study 
was to further investigate the IHC expression of 
cyclin D1 in the context of CD99 in EWS and 
RMS paraffin-embedded tissue. This was done 
to explore how this combination of markers could 
contribute to the differential diagnosis of these 
lesions.  
 
Patients and Methods 
In a cross-sectional study, approved by the 
Ethics Committee of Iran University of Medical 
Sciences (code No.: 2218), we assessed and 
compared the extent and intensity of cyclin D1 
and pattern of CD99 expression in formalin fixed 
paraffin-embedded tissues of EWS and RMS.  
IHC was performed on a 4 µm tissue section 
using mouse monoclonal antibody anti-human 
CD99 (company, country, cat num) and anti-
human cyclin D1 (company, country, cat num). 
We carried out staining according to the 
manufacturer's instructions and using the envision 
method. In brief, sections were mounted on poly-
l-lysine coated slides and dried in an oven at 60°c 
for 60 min. Following deparaffinization and 
rehydration, we immersed the tissue sections in 
methanol containing 0.3% hydrogen peroxide for 
20 min so as to block the potential endogenous 
peroxidase activity. Subsequently, the sections 
underwent antigen retrieval process by autoclaving 
in citrate buffer (pH=6) for 10 min. The sections 
were then incubated with primary antibody for 1 
h at an optimal dilution of 1/50 and secondary 
antibody (Envision System, Dako, Denmark) for 
30 min. Afterwards, the sections were treated 
with 3.3'-Diaminobenzidine (DAB, Dako) as the 
chromogen and counterstained with hematoxylin 
(Dako). Finally, after the dehydration steps, we 
mounted the sections under glass coverslips and 
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analyzed them under a light microscope. For 
negative control slides, the primary antibody was 
replaced with washing buffer. 
Using the Allred scoring method, we semi-
quantitatively scored the expression extent and 
intensity of cyclin D1 immunoreactivity . In this 
respect, we recorded the intensity as 0 (negative) 
when no staining of the tumoral cells’ nuclei was 
observed even at high magnifications, 1 (weak) 
if staining was visible only at high magnifications, 
2 (moderate) when staining was readily visible 
at low magnifications, and 3 (strong) if staining 
was strikingly positive even at low power 
magnifications.13 The expression pattern was 
stratified as negative, focal, heterogeneous, or 
diffuse. We categorized the CD99 expression 
pattern into three groups, namely negative, 
membranous, and cytoplasmic.14 
 
Statistical analysis 
The mean and standard deviation (SD) showed 
the central tendency and variability for continuous 
variables, respectively. Categorical variables were 
compared using chi-square test or Fisher's exact 
test. P-Values less than 0.05 were considered as 
statistically significant. All statistical analyses 




In total, 30 EWS patients (19 males and 11 
females) and 22 RMS patients (11 males and 11 
females) were enrolled in this study. The mean 
age of EWS and RMS patients was (18.23±10.4) 
and (9.5±14.3) years, respectively. Regarding 
tumor location, 43.3% of EWS cases were located 
in long bones while 20% and 36.7% were located 
in flat bones and soft tissues, respectively. In 
RMS patients, 40.9% and 59.1% of the cases 
were located in soft tissues and mucosal tissues, 
respectively. 
While CD99 pattern was membranous in all 
EWS tumors (100%), it was negative in 86.4% 
of RMS tumors and cytoplasmic in 9.1% (P< 
0.001). A strong cyclin D1 intensity was observed 
in 2/3 of EWS tumors; whereas, moderate intensity 
was observed in the remaining 1/3 of EWS tumors. 
By contrast, 45.5% of RMS sections demonstrated 
negative cyclin D1 intensity, followed by 31.8% 
and 22.7% presenting with week and moderate 
intensity, respectively (P< 0.001) (Figure 1). The 
two types of tumors were significantly different 
regarding cyclin D1 extension pattern  such that 
93.3% of EWS sections showed diffuse pattern 
of cyclin D1; however, 90% of those with RMS 
demonstrated negative or focal extension pattern 
of cyclin D1 (P< 0.001) (Figure 2). Table 1 shows 
the demographic and pathologic characteristics 
of the patients in detail. 
There was no significant association between 
the demographic characteristics of the patients 
and the expression patterns of CD99 and cyclin 
D1. Moreover, we did not observe a significant 
relationship between the location of the tumors 
and the expression patterns of CD99 and cyclin 
D1. 
Figure 1. Positive cyclin D1 immunostaining in Ewing’s sarcoma: A) H&E section B) Diffuse positive immunostaining pattern. 
A B
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Discussion 
Our results showed the moderate to strong 
intensity of cyclin D1 in EWS sections; however, 
the intensity of cyclin D1 was negative or week 
in the majority of RMS sections (17 out of 22 
cases). In this respect, no strong cyclin D1 
intensity existed in the cases of the latter group, 
while it was seen in two thirds of EWS lesions. 
In addition, the pattern of expression was diffused 
in the majority of EWS cases (28 out of 30 cases) 
and negative or focal in the majority of RMS 
sections (20 out of 22 cases). In this regard, there 
was no diffused expression pattern of cyclin D1 
in RMS tissues’ staining.  Our investigation further 
demonstrated a membranous pattern of CD99 in 
all EWS tissues while CD99 expression was 
negative in the majority of evaluated RMS sections 
(19 sections) and positive in only three sections 
(two cytoplasmic and one membranous). Based 
on these results, it can be concluded that the 
Table 1. The clinicopathologic and demographic characteristics of the patients 
Characteristics EWS (n=30) RMS (n=22) 
Age 18.23±10.4 9.5±14.3 
Gender 
Male 19 (63.7) 11 (50) 
Female 11 (36.7) 11 (50) 
Location 
Long bone 13 (43.3) -  
Flat bone 6 (20) - 
Soft tissue 11 (36.7) 9 (40.9) 
Mucosal Tissue - 13 (59.1) 
CD99 pattern  
Negative - 19 (86.4) 
Membranous 30 (100) 1 (3.2) 
Cytoplasmic - 2 (9.1) 
Cyclin D1 intensity 
Negative - 10 (45.5) 
Week - 7 (31.8) 
Moderate 10 (33.3) 5 (22.7) 
Strong 20 (66.7) 0 
Cyclin D1 pattern 
Negative - 10 (45.5) 
Focal - 10 (45.5) 
Heterogeneous 2 (6.7) 2 (9) 
Diffused 28 (93.3) - 
EWS: Ewing’s sarcoma; RMS: Rhabdomyosarcoma; Data are shown as mean±SD or number (%).
Figure 2. Negative cyclin D1 immunostaining in rhabdomyosarcoma: A) H&E section B) Negative immunostaining pattern. 
A B
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strong intensity and diffused expression pattern 
of cyclin D1 and the membranous pattern of 
CD99 favor the diagnosis of EWS; therefore, 
cyclin D1 could be suggested as a reliable 
complementary marker in the differential diagnosis 
of EWS and RMS, particularly when their dif-
ferentiation imposes a challenge.    
Despite the development of several IHC 
diagnostic markers for small round blue cell 
tumors, the differential diagnosis of these lesions 
is still challenging and poses serious problems 
in certain cases. Among the pediatric small round 
blue cell tumors, it might be more challenging to 
differentiate EWS from alveolar RMS.4 
Consequently, it is highly necessary to identify 
reliable IHC markers for the diagnosis of EWS 
and RMS.  
Cyclin D1 is a protein required for the 
progression of cell proliferation through G1 phase 
of the cell cycle.15 Deregulation of cycline D1 
has been reported in several types of cancer and 
its overexpression has been correlated with shorter 
survival and increased metastasis rates.16 Analysis 
of cyclin D1 expression also provides vital 
diagnostic information regarding carcinogenesis 
and contains prognostic values in several 
cancers.17 Its deregulation in small round blue 
cell tumors has also been recently reported.18,19 
Accordingly, we aimed to further evaluate the 
diagnostic value of cyclin D1 in the differentiation 
of EWS from RMS. 
Fuchs et al. evaluated the expression of cyclin 
D1 in EWS sections for the first time in 2004.  
They stained 31 tissue samples from patients 
suffering from EWS with antibodies against cyclin 
D1. Based on their report, positive cyclin D1 
staining was present in 42% of all evaluated 
tumors. There was no report on the intensity and 
expression pattern of cyclin D1 in their study. 
They concluded that cyclin D1 overexpression 
is of importance in EWS pathogenesis.19 In line 
with this evidence, Margo et al. decided to evaluate 
the diagnostic potential of cyclin D1 in 2015. 
They performed a comparative IHC analysis on 
the expression and distribution of cyclin D1 in a 
large series of soft tissue EWS/pPNETs and RMS 
(both embryonal and alveolar subtypes) to assess 
its potential usefulness in their differential 
diagnosis. Based on their report, cyclin D1 was 
strongly and diffusely expressed in all cases 
(20/20) of EWS/pPNET, while it was absent in 
all RMS cases (15/15). They concluded that a 
strong and diffuse nuclear expression of cyclin 
D1 is of complementary diagnostic value to CD99 
and FLI-1 in confirming the diagnosis of 
EWS/pPNET, and ruling out RMS.3, 18 
Although our results are very similar to that 
of Margo’s study, some minor differences can 
also be observed. As the most important difference, 
the intensity of cyclin D1 was moderate in one 
third of our patients, while strong in all patients 
of Margo’s study. This inconsistency could be 
attributed to the difference in tumor characteristics. 
While both intra- and extra-osseous EWS patients 
were included in our study, Margo et al. only 
included soft-tissue EWS in their study.18 
Moreover, the stage of the included tumors 
was not considered in either studies. This could 
be considered as the biggest limitation of the 
present study. Potentially, staging is able to 
influence the expression pattern of markers, where 
a higher expression is expected at higher stages. 
Therefore, this feature is recommended for 
consideration in future investigations. Among 
other limitations of our study, we can mention  
the lack of confirmatory molecular tests and the 
limited sample size. An important strength of this 
study is the precise evaluation of IHC patterns 
of staining in the examined tumors. 
 
Conclusion 
Consistent with previous studies, our results 
showed that CD99 is an important primary marker 
for the differentiation of EWS and RMS, and 
cyclin D1 is a complementary immunomarker of 
EWS. Moreover, given different expression pattern 
of cyclin D1 in EWS and RMS, it may 
successfully be used in differentiating EWS from 
RMS when their differentiation is challenging.  
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